Zinger Key Points
- JPMorgan raises EverQuote's price target from $25 to $29, citing strong Q4 results and first-quarter revenue guidance above estimates.
- Analyst says EverQuote's guidance is 15% above estimates, with potential for upside as carriers remain inactive and some states are closed.
- Get access to your new suite of high-powered trading tools, including real-time stock ratings, insider trades, and government trading signals.
EverQuote, Inc. EVER shares are trading higher on Tuesday. On Monday, the company reported fourth-quarter results and issued first-quarter revenue guidance above estimates.
The company reported EPS of $0.33, missing the $0.39 estimate, while sales of $147.46 million exceeded the $133.86 million estimate.
EverQuote expects first-quarter FY25 sales of $155 million-$160 million vs. consensus of $136.86 million and adjusted EBITDA of $19 million-$21 million.
JPMorgan analyst Cory A. Carpenter raised the price forecast from $25 to $29 and reiterated an Overweight rating, reflecting upward estimate revisions and the removal of the 1×1 consent overhang.
The analyst said the company has continued the trend of exceeding expectations, with revenue surpassing the upper end of guidance by 8%, driven by auto carriers increasing customer acquisition spending late in the quarter.
EverQuote’s first-quarter guidance was 15% higher than Street estimates, partly due to fewer challenges from the vacated 1×1 consent rule, added the analyst.
Carpenter wrote that while revenue growth was expected to normalize around 15%-20% through the year, he saw the potential for further upside as several carriers remained inactive and some states were still largely closed.
Also, Needham analyst Mayank Tandon maintained a Buy rating and raised the price forecast from $30 to $38.
Investors can gain exposure to the stock via Inspire Fidelis Multi Factor ETF FDLS.
EVER Price Action: EverQuote shares are up 18.71 % at $23.92 at publication Tuesday.
Read Next:
Photo: Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.